Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575736 | 0.80 | PTGDR2 (0.54) | PTGDR2PKMPOLBSMN1; SMN2 | |
| SCHEMBL1508488 | 0.80 | L3MBTL1 (0.61) | PTGDR2PKMFFAR4RORCPOLB | |
| SCHEMBL21497919 | 0.79 | PKM (0.55) | PTGDR2PKMPOLBSMN1; SMN2 | |
| SCHEMBL14277742 | 0.77 | PTGDR2 (0.41) | PTGDR2FFAR4RORCCTSA | |
| SCHEMBL30568364 | 0.76 | GPR3 (0.46) | POLB | |
| SCHEMBL1753426 | 0.75 | PTGDR2 (0.73) | PTGDR2PKM | |
| SCHEMBL1690254 | 0.74 | PTGDR2 (0.77) | PTGDR2POLBSMN1; SMN2 | |
| SCHEMBL1690271 | 0.74 | PTGDR2 (0.67) | PTGDR2PKM | |
| SCHEMBL30537993 | 0.74 | L3MBTL1 (0.59) | PTGDR2PKMPOLBSMN1; SMN2 | |
| SCHEMBL1690214 | 0.74 | PTGDR2 (0.77) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1848687-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F. Hoffmann-Roche AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| US-20060178532-A1 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006082010-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178532-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | PTGDR2 545/4885PKM 3251/4885FFAR4 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.